Close Menu

Fluidigm

The GenomeWeb Index outperformed the Dow Jones and the Nasdaq, but underperformed the Nasdaq Biotechnology Index this month.

The firm will use the net proceeds to repurchase up to about $50 million of its senior convertible note due 2034, as well as for general corporate purposes.

Fluidigm logged $26.4 million in revenues compared to $29.0 million a year ago and well short of analysts' consensus estimate of $28.7 million.

The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

Fluidigm will develop a microfluidic device for single-cell measurement of epigenetic changes under a broader $27.8 million DARPA-funded project.

The method combines DNA-barcoded antibodies with signal amplification for multiplexed protein imaging at subcellular resolution and relatively high throughput.

Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.

Year-over-year revenues increased on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.